Dementia and Alzheimer's Disease Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F

The Global market for dementia and Alzheimer's disease treatments is anticipated to expand from USD 12.18 billion in 2025 to USD 17.91 billion by 2031, reflecting a compound annual growth rate of 6.64%. This sector includes both medical and non-medical therapies designed to manage the behavioral issues and cognitive deterioration linked to neurodegenerative disorders like Alzheimer's. Growth is largely fueled by the rising global incidence of dementia linked to an aging demographic, increased awareness resulting in prompt diagnoses, and substantial financial backing for research aimed at uncovering disease mechanisms and new treatment targets. In October 2025, the World Medical Association referenced the World Health Organization, noting that approximately 55 million people worldwide were living with dementia in 2023.

Market progress is additionally supported by improved diagnostic tools and growing healthcare systems worldwide. Nevertheless, a major obstacle to this expansion is the high expense and extended time required to develop and secure regulatory clearance for novel therapies, coupled with the limited success of current treatments in truly changing the course of the disease.

Market Driver

Progress in disease-modifying treatments is profoundly influencing the worldwide market for Alzheimer's and dementia care by delivering therapies that target the root causes of the condition instead of just alleviating symptoms. The rollout of innovative drugs that can slow the disease's advancement or clear harmful proteins is changing how these conditions are treated, bringing renewed optimism to affected individuals and their loved ones. The rising commercial adoption of newly authorized medications highlights this shift; Biogen's Q4 2025 financial results from February 2026 revealed that global sales for Leqembi (lecanemab) reached roughly $134 million. This reflects a clear market demand for mechanism-targeting treatments, which in turn spurs further investment and innovation in the field, broadening treatment options and motivating earlier diagnostic initiatives to find suitable candidates.

Alongside these clinical breakthroughs, increased funding for research and development acts as a major driver for market expansion. Boosted financial support from private and public entities powers the complex and expensive journey of drug discovery, laboratory testing, and clinical evaluations for novel Alzheimer's and dementia therapies. Such funding speeds up the development process by backing various investigative strategies, such as studying new biomarkers, genetic factors, and distinct disease pathways.

In July 2025, the Alzheimer's Association highlighted in the report 'Senate Appropriations Committee Approves $100 Million Increase for Alzheimer's Research' that the Senate Appropriations Committee authorized a $100 million boost in research funding for dementia and Alzheimer's at the National Institutes of Health for fiscal year 2026. This ongoing financial dedication is essential due to the massive economic impact of these illnesses; the Alzheimer's Association estimated that U.S. health and long-term care expenses for those with dementia would hit $384 billion in 2025, underscoring the critical need to fund solutions for this challenging condition.

Market Challenge

The substantial expenses and extended periods needed to create and secure regulatory clearance for new therapies severely hinder the expansion of the worldwide dementia and Alzheimer's disease treatment sector. The massive capital required to advance a medication from initial discovery across various clinical trial stages to final market approval, combined with the lengthy timeframes required for each phase, establishes a massive hurdle for pharmaceutical developers.

This obstacle is worsened by the exceptionally high failure rates seen in the development of drugs for neurodegenerative conditions, as many prospective treatments do not show adequate safety or effectiveness during advanced clinical trials. These setbacks result in wasted financial resources and extend the delay for patients desperate for helpful interventions. In 2024, the Biotechnology Innovation Organization (BIO) noted that the success rate for new therapeutic candidates navigating clinical development was merely 6.7 percent across all medical conditions. Such poor odds of regulatory success discourage financial backing for central nervous system treatments, ultimately limiting the flow of groundbreaking therapies required for the market to grow.

Market Trends

A major movement reshaping the worldwide market for Alzheimer's and dementia therapies is the increasing transition toward customized medical strategies. This approach seeks to customize care using a patient's distinct genetic background, biomarker indicators, and disease trajectory, departing from universal treatment models. Personalized methods are vital because Alzheimer's is a complex disease, causing individuals to react differently to various medications.

This shift is supported by heavy funding in specialized studies; on January 8, 2026, the Alzheimer's Association announced in 'Alzheimer's Association Part the Cloud Grants $11 Million to Develop Innovative Treatments' that its program awarded over $11 million to fund groundbreaking therapies, acknowledging personalized medicine as the next frontier in Alzheimer's care. Such initiatives aim to pinpoint specific patient groups that will gain the most from targeted treatments, ultimately boosting success rates and ensuring better use of resources in both research trials and everyday medical settings.

An additional key trend is the ongoing progress in early detection using biomarkers, which is essential for initiating prompt treatment, especially since disease-modifying drugs work best during the initial phases of cognitive impairment. Breakthroughs in this field, notably involving blood-based biomarkers, are making testing more accessible while lowering the expenses and discomfort linked to conventional procedures like cerebrospinal fluid tests and PET scans.

This momentum is supported by major financial commitments designed to create advanced diagnostic instruments; on March 17, 2026, the Alzheimer's Drug Discovery Foundation (ADDF) revealed in 'ADDF Launches New Phase of $150 Million Diagnostics Accelerator Initiative to Power Next Generation of Alzheimer's Precision Medicine Worldwide' an extra $50 million for its Diagnostics Accelerator, increasing the program's total funding to $150 million to push forward these vital biomarker technologies. These improvements in diagnostics allow for the faster identification of patients, a crucial step for optimizing the effectiveness of new therapies and properly categorizing participants for clinical research.

Key Market Players

• Merz Pharma GmbH & Co. KGaA
• Novartis AG
• Pfizer, Inc.
• Ono Pharmaceutical Co., Ltd.
• Johnson & Johnson Services, Inc.
• H. Lundbeck A/S
• F. Hoffmann-La Roche Ltd.
• AbbVie Inc.
• Eli Lilly and Company
• Corium, Inc.

Report Scope

In this report, the Global Dementia and Alzheimer’s Disease Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Dementia and Alzheimer’s Disease Treatment Market, By Drug Class:

• Cholinergic/ Cholinesterase (ChE) Inhibitors
• Memantine
• Combination Drugs
• Others

Dementia and Alzheimer’s Disease Treatment Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Dementia and Alzheimer’s Disease Treatment Market, By Region:

• North America
• Europe
• Asia Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Dementia and Alzheimer’s Disease Treatment Market.

Available Customizations

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.